Deals
Viatris Considers Sale of $3 Billion European OTC Assets
- US drugmaker is working with adviser Jefferies to find buyers
- Assets could draw interest from both PE and strategic bidders
This article is for subscribers only.
Viatris Inc. is considering a potential sale of its consumer-health assets in Europe, in a deal that could fetch more than €3 billion ($2.9 billion) for the US drugmaker, according to people familiar with the matter.
The Canonsburg, Pennsylvania-based company is working with investment bank Jefferies Financial Group Inc. as it seeks to identify potential suitors for the business, the people said, asking not to be identified as the matter is private.